Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide/dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma
2010-020347-12Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of elotuzumab in multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Started Apr 2011; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2010-020347-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020347-12.